ArticleJournal of nanobiotechnology2026
A PEGylated nanobody against HBsAg exhibits pleiotropic antiviral efficacy in hepatitis B models.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hepatitis B virus (HBV) remains a global health burden, with current therapies rarely achieving functional cure, highlighting an unmet need for novel strategies. Here, we isolate a high-affinity nanobody, VHH4917, against the viral surface antigen (HBsAg) from an alpaca nanobodies phage library. VHH4917 exhibits a multi-phenotypic antiviral profile that extends beyond mere neutralization. It not only accelerates HBsAg clearance in vivo but also potently suppresses HBV replication, transcription, and particle secretion through distinct mechanisms. Further engineering by site-specific PEGylation markedly prolongs its circulating half-life and enhances in vivo antiviral efficacy in mouse models of chronic HBV infection. Our work characterizes VHH4917 as a potent, novel therapeutic candidate and provides a promising protein-engineering framework for advancing nanobody-based immunotherapy against chronic hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.